La Chandra Pharmalab

What La Chandra Pharmalab does

La Chandra Pharmalab (legal entity: La Chandra Bioscience P Ltd) is a cGMP-compliant Indian manufacturer of niche Active Pharmaceutical Ingredients (APIs), with a specialized focus on hormone APIs. Founded in 2015 and headquartered in Ahmedabad, Gujarat, the company operates three dedicated hormone production plants within a 10,000 square metre cGMP-designed facility, with total production volume exceeding 30,000 litres. Manufacturing capabilities are built around multi-stage synthesis, advanced photoreactor suites for photochemical synthesis, and preparative chromatography for purification of complex molecules, supported by a 21 CFR Part 11 compliant QC laboratory, dedicated R&D facilities recognized by India's Department of Scientific and Industrial Research (DSIR), and a zero liquid discharge environmental infrastructure partially powered by a 670 kWh solar facility (planned to scale to 1,200 kWh).

The company serves pharmaceutical formulation companies globally, with active distribution across regulated markets (US, EU, Brazil) and ongoing expansion into Canada, Mexico, Korea, Japan, and China. Its revenue model is anchored on B2B sales of in-house hormone APIs, supplemented by contract manufacturing of customer-specific APIs, process R&D services, analytical development laboratory (ADL) services, quality control testing, and technology transfer services. The go-to-market motion is enterprise field sales involving direct technical engagement with formulation companies on API specifications, regulatory documentation, and long-term supply agreements. Pricing is contract-negotiated and not publicly disclosed. Regulatory compliance spans ICH Q7, EMA EudraLex Vol. 4 GMP Part II, 21 CFR Parts 210, 211, and 11, India's Schedule M, and the Drugs & Cosmetics Act.

La Chandra is privately held, founder/management-led (Managing Director Priyvrat Gadhvi), with no disclosed external institutional investment or venture capital backing. The company employs 51–100 staff, suggesting a mid-sized contract development and manufacturing organization (CDMO) profile concentrated in a narrow but high-value therapeutic category (hormones). Operations are concentrated in a single Gujarat site, with export-driven revenue from regulated and semi-regulated international markets serving as the primary growth vector.

Name

La Chandra Pharmalab

Legal name

La Chandra Bioscience P Ltd

Website

https://lachandra.in

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

La Chandra Pharmalab is a cGMP-compliant Indian pharmaceutical manufacturer specializing in niche hormone Active Pharmaceutical Ingredients. It serves global formulation companies with multi-stage synthesis, photochemistry, and preparative chromatography capabilities across three manufacturing plants, exporting to regulated markets.

Ownership category

akta.pro rank

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure

Revenue model

1. Active Pharmaceutical Ingredient (API) Sales: La Chandra Pharmalab generates revenue through the manufacturing and sale of niche Active Pharmaceutical Ingredients, particularly hormones, to pharmaceutical formulation companies worldwide. Revenue is derived from both in-house product pipeline and contract manufacturing services for customer-specific APIs. Production capacity exceeds 30,000 litres across three dedicated hormone production plants.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

La Chandra Pharmalab researches, develops, and manufactures niche Active Pharmaceutical Ingredients (APIs), with a specialized focus on hormones. The company operates three dedicated hormone production plants across a 10,000 sq metre cGMP-compliant facility in Ahmedabad, India, offering both in-house product pipelines and contract manufacturing services for pharmaceutical formulation companies worldwide.

Product overview

La Chandra Pharmalab operates as a cGMP-compliant pharmaceutical manufacturer specializing in niche Hormone Active Pharmaceutical Ingredients (APIs). The company's product portfolio centers on hormone API manufacturing as its core product, supported by complementary contract manufacturing services across three dedicated production plants with over 30,000 litres total capacity. Value-added services include process R&D, analytical development, quality control testing, and technology transfer. The company exports to regulated markets including US, EU, Brazil and expanding to Canada, Mexico, Korea, and Japan. Operations are structured around integrated manufacturing, quality assurance, R&D, warehouse, and environmental protection capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Hormone Active Pharmaceutical Ingredients (APIs)

Quantifiable outcome

• Total production capacity of over 30,000 litres across three dedicated hormone production plants
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Sun Pharmaceutical Industries: India's largest pharmaceutical company with integrated API manufacturing across many categories serving regulated global markets. Comparable on API operations and cGMP quality systems, but a broad incumbent where APIs are one of many business lines rather than a focused niche play.
• Aurobindo Pharma: Large Indian pharmaceutical company with substantial in-house API operations across multiple therapeutic categories including steroids/hormones, serving global markets. Comparable in API manufacturing capability but operates at much greater scale and breadth (finished-dose as well), making it a broad incumbent rather than a pure-play peer.

Direct peers

• Piramal Pharma Solutions: India-headquartered CDMO offering API development and manufacturing across multiple plants with global regulatory inspections. Overlaps directly with La Chandra on small-molecule API commercialisation, process R&D services, and technology-transfer work for global pharma formulation clients.
• Divis Laboratories: One of India's largest API manufacturers with significant custom synthesis and contract API manufacturing serving global regulated markets. Comparable for API process chemistry, multi-plant cGMP operations, and B2B formulation-customer base, but at considerably larger scale.
• Hovione: Portugal-headquartered CDMO specialising in small-molecule API process development and commercial manufacturing, including complex chemistry and steroidal hormones. Comparable for shared focus on difficult-to-make small-molecule APIs under global regulatory standards and a similar photochemistry/particle-engineering tech stack.
• Neuland Laboratories: Indian CDMO focused on small-molecule API process R&D, contract manufacturing, and peptide APIs serving global pharma. Comparable in niche-API positioning, technology-driven synthesis work, and dependence on US/EU regulated-market customers.
• Cambrex Corporation: US-headquartered CDMO specialising in small-molecule API development and manufacturing with multiple regulated facilities. Comparable to La Chandra on cGMP API manufacturing, technology transfer services, and tier-1 regulatory positioning for global formulation clients.
• Symbiotec Pharmalab: India-based, hormone-focused API manufacturer producing steroid and hormone APIs under cGMP for global pharma formulators. Symbiotec is the closest strategic analogue to La Chandra given shared India base, hormone specialisation, and identical regulatory/compliance model targeting the same formulation customer base.
• MSN Laboratories: Indian API manufacturer with active pharmaceutical ingredient development across multiple therapeutic categories including hormones, exporting to regulated markets. Comparable in product type (small-molecule APIs including hormones), regulatory positioning, and B2B formulation-customer focus.
• Carbogen Amcis (formerly Dishman): India-rooted, Switzerland-headquartered CDMO with strong capabilities in HPAPI and complex small-molecule API manufacturing including steroids. Comparable to La Chandra in serving regulated markets, operating multiple plants with cGMP compliance, and combining API development with contract manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/la-chandra-bioscience-p-ltd

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about La Chandra Pharmalab